Sep 27, 2019 / 07:00PM GMT
Susan Vissers Lisa - Boston Scientific Corporation - VP of IR
Hi, guys. It's noon, so we're going to get started. As people are getting settled, thank you very, very much for joining us here at the Boston Scientific Transvascular Cardio Therapeutics Conference 2019.
Really grateful for the opportunity here. And my name is Susie Lisa, I'm with the Investor Relations team at Boston Scientific, joined by my colleague Lauren Tengler. We have a great lineup of speakers for you today. We'll try and keep it tight to about 15 to 20 minutes of prepared remarks and then leave lots of time for your questions.
So to move right into, we will be making forward-looking statements today, and the usual regulatory disclaimers apply as well as from financial disclaimers, we encourage you to seek our latest 10-K and 10-Q filings with the SEC for a full discussion of risk factors.
And with that, I'm very happy to turn it over to Jeff Mirviss, our Senior Vice President and President of Peripheral Interventions. Thanks, Jeff.
Jeffrey B. Mirviss - Boston Scientific
Boston Scientific Corp Investor Update at TCT 2019 Transcript
Sep 28, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers